Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Orteronel Leaves Hole In Millennium/Takeda Pipeline

This article was originally published in PharmAsia News

Executive Summary

The non-steroidal androgen synthesis inhibitor failed to show a survival benefit in chemotherapy-naïve prostate cancer patients after also failing in post-chemo patients in 2013. With Takeda ending development of the Phase III candidate, its Millennium cancer pipeline is reduced to a pair of Phase III candidates.

You may also be interested in...



Bayer Looks For New Partner As It Strives To Be A Player In Oncology Market

Nearly a decade after entering the oncology field, Bayer has three products on the market, two candidates in Phase II trials and a dozen more in Phase I trials; at ASCO it will talk to a potential partner about a combination drug study.

Takeda’s Tachi Yamada Discusses The Late-Stage Pipeline: An Interview At PSA 2013

In an interview with “The Pink Sheet” at Elsevier’s PSA 2013 conference, Takeda’s R&D chief spoke of progress in building a global vaccine business and of the key late-stage assets that will carry the company into the next decade.

Takeda Has One Shot Remaining With Orteronel In Prostate Cancer

Phase III ELM-PC 5 study of orteronel in post-chemo metastatic castration-resistant prostate cancer is unblinded after drug fails to improve overall survival. But the company is continuing a Phase III trial in an earlier line of therapy.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC087461

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel